TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With a Shift in Choroid Status at Month 12 in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of self-care dialysis or receipt of transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Use of permanent vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood pressure control at RRT initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Second ACL Injury
Endpoint domain: Adverse events/effects
Primary endpoint: Prolongation and normalization of anal CEP responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prolongation and normalization of rectal CEP responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prolongation and normalization of anal MEP responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prolongation and normalization of rectal MEP responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic Quality of Visualization of Coronary Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contrast Density (CD) Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Validity (Sensitivity and Specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoroughness to report molecular profiling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevention of nausea and vomiting events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalized Accelerometric Tremor Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cough reflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dropout rate secondary to adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of the QUIP-RS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute Change From Baseline Score for the VVSymQ (Total Score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Silver level in hair samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride level in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Silver level in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal transit-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion hospitalized or used emergency department without hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Progression-Free Survival (PFS) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC 0-24hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration at 24 Hrs Post-dose (C24hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS score at 72 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: differences in msRankin score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Grade 2 or Higher Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Pigmentation Improvement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prostate Specific Antigen (PSA) Failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity of the model
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients achieving a clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wechsler Preschool and Primary Scales of Intelligence, 3rd ed.
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Physiological Patterns of Coronary Artery Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of intraoperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreous clear-up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of creatinine height index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall Respiratory alarm rate per patient per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Motor Function Measure (MFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative morbidities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent of Days Adhered to TRE Dietary Pattern
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short-term lower-leg growth rate (LLGR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Juniper Asthma Quality of Life Questionnaire (AQLQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood flow measurements from the lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Reduction of respiratory fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in macular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of heart rate after submax exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: measurement of protein requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minutes of Wake After Sleep Onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep Efficiency (SE)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of procedures completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Capacity of T cells to proliferate in response to antigen stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in antigen-specific humoral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of lymphocyte subsets and NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma glutamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of gestational diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of allergy in child
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change From Baseline in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defective volume of myometrium at cesarean section scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of axial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum Weight Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FEV1 TAUC0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measure of PSA (Prostate Specific Antigen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of symptomatic adverse anastomotic events
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration at the end of infusion (CEOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial area under the serum concentration-time curve (AUC0-7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T> minimal inhibitory concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the curve (AUC) / minimal inhibitory concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful performance of percutaneous transapical TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive DFL symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life - change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver Health - change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change of migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline and placebo in blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change from baseline in 12-lead electrocardiogram (ECG) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Depression Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin tape stripping (STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Symptom Severity using PTSD Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Anxiety Symptoms using Generalized Anxiety Disorder Scale (GAD-7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of Functional Impairment using the Range of Impaired Functioning Tool (RIFT)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood volumes obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variability of the center of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number, type and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Week 12 in Schirmer Test (ST) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 in Tear Break-Up Time (BUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With >25% Improvement in Fluorescein Staining of the Cornea (FS) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Fructosamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of dental plaque build-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced risk of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Abnormal Hepatic Test Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual assessment (Patch assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in General Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Social Development
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Patients Reporting Dose Limiting Toxicities (DLTs) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Roland-Morris Disability Questionnaire (RDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ≥ 20 Points
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Conners Adult ADHD Rating Scales (CAARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalogram (EEG) Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amount of Tau Accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Surface Microhardness Recovery (%SMHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Prandial Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endoscopically effective improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopically complete improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observance to the physical activity program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of subjects reporting local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitative fecal fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Muscle Sympathetic Nerve Activity (MSNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of AKI at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immune-related severe adverse events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Cobalt, Chromium and Molybdenum ions in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of N6022
Endpoint domain: Adverse events/effects
Primary endpoint: Natural history of ADPKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Sensory Organization Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic Gait Index and Functional Gait Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Five Times Sit to Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-emergent adverse events (TEAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean area under the curve (AUC) of the NRS scores through 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Six Minute Walk Test - Distance Traveled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Treadmill Velocity - Self Selected Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HeartHome patient referrals into the HeartHome program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of HeartHome patient referral into the HeartHome program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of HeartHome patient enrollments in the HeartHome program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Clinical Specialist Treatment Decision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sleeping schedules
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pulmonary Endothelial Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Related Adverse Events for Hepatic Injury
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Related Adverse Events for Neurological status
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events for Pulmonary Status
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to safely deliver the combination of mitomycin C and veliparib
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to safely deliver veliparib in a continuous dose as monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of screening for FA deficiency across different tumor types
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of meningitis (viral or bacterial)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage change in PD-L1 expression in NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in PD-L1 expression in melanoma lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Child Body Mass Index (BMI) Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of blisters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gait Spatio-Temporal Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Quality of Life Inventory (PEDS-QL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The number of subjects who experience potential clinically significant changes in vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: The number of subjects who experience potential clinically significant changes in safety labs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adequate bowel preparation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for using any additional diagnostic tool
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiac response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma glucose kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent change in bone mineral density of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants experiencing any Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants experiencing Adverse Event of Interest (AE-I)
Endpoint domain: Adverse events/effects
Primary endpoint: Within-participant linear change in combined z-score for cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Improvement on the Multiple Sclerosis Walking Scale (MSWS-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Anxiety Related Emotional Disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fracture displacement during healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of unplanned cardiovascular hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Current Use of Highly Effective Contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eradication of Group A Streptococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Freedom from AF and other atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: biopsy proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: WOMAC pain and functional scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful Withdrawal of Immunosuppressive Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Body Temperature Abnormalities and/or Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reactogenicity Assessed by Number of Solicited Local Reactions
Endpoint domain: Adverse events/effects